TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03055455

Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
Study: NCT00408876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03500965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Description: control condition (no image)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Description: control condition (no image)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graphic PWL
Description: pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers
Study: NCT03477448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purified Protein Derivative
Description: is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest
Study: NCT03500965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers
Study: NCT01016860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
Study: NCT02561390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin prick test
Description: skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin prick test
Description: skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific IgE measurement
Description: measure specific IgE of American cockroach, dog, cat, dust mite and mold

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific IgE measurement
Description: measure specific IgE of American cockroach, dog, cat, dust mite and mold
Study: NCT03920436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: infrared water group
Description: This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: This group takes 1,8 L of drinking water using a tumbler at room temperature.
Study: NCT03032497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based BCI analysis of fear avoidance
Description: Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
Study: NCT01288833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close focus HD NBI Colonoscopy System
Description: Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
Study: NCT02472977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulocuplumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulocuplumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study: NCT00072033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and Docetaxel
Description: cisplatin and docetaxel chemo- and radiochemotherapy
Study: NCT01555606

Intervention type: OTHER
Intervention: No intervention
Description: Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
Study: NCT02926391

Intervention type: DEVICE
Intervention: UNiD 3D VBR
Description: Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion

Intervention type: DEVICE
Intervention: UNiD 3D VBR
Description: Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
Study: NCT02115737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation group treatment
Study: NCT04663269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg PF Dexamethasone
Description: analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Control Test
Description: Peritubal block - standard local analgesic administration
Study: NCT04881890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diabetes Prevention Program
Description: LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
Study: NCT03028194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No procedure after delivery of the placenta
Study: NCT04672057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of gait parameters
Description: Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of gait parameters
Description: Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of gait parameters
Description: Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
Study: NCT00863369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01754181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: the intervention is applied only at the dose of insulin
Study: NCT03083054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells electroporated with WT1 mRNA
Description: Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
Study: NCT00299728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Protein Vaccine
Description: NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Protein Vaccine
Description: NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
Study: NCT02748005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek seeds extract 500 mg
Description: one cap once a day
Study: NCT02662322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic communication
Description: hypnotic communication during peripheral intravenous catheterization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative connotation communication
Description: negative connotation communication during peripheral intravenous catheterization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: neutral connotation communication
Description: neutral connotation communication during peripheral intravenous catheterization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral intravenous catheterization
Description: peripheral intravenous catheterization
Study: NCT00654303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT02048254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Study: NCT03406130

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Procedure
Description: Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Procedure
Description: Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision surgery
Description: The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
Study: NCT02059733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT04347590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded - CGM (Medtronic Guardian)
Description: Data from device will be readable and alarms on

Intervention type: DEVICE
Group type: OTHER
Intervention: Blinded - CGM (Medtronic Guardian)
Description: Data from device will be blinded and alarms off
Study: NCT00754195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
Study: NCT01955603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0215-0384
Description: A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered corresponding to NNC0215-0384 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered corresponding to NNC0215-0384 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered corresponding to NNC0215-0384 treatment
Study: NCT00382291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Titration
Description: Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
Study: NCT04785404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary skin closure
Description: skin will be stitched after stoma reversal to heal by primary intention
Study: NCT00382291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow Titration
Description: Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
Study: NCT02066389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration
Study: NCT02884622

Intervention type: OTHER
Group type: OTHER
Intervention: nasal epithelial
Description: CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
Study: NCT05494775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-vascular endothelial growth factors (Anti-VEGFs)
Description: Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-vascular endothelial growth factors (Anti-VEGFs)
Description: Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Study: NCT00839800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Description: 160/4.5 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: 160/4.5 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline Turbuhaler
Description: 0.4 mg
Study: NCT02502851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Atherectomy
Description: Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
Study: NCT00450099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
Study: NCT03632928

Intervention type: OTHER
Intervention: Ultrasound Elastography
Description: Measuring muscle hardness at the trapezius and neck bilateral

Intervention type: OTHER
Intervention: Pressure Pain threshold
Description: Measuring Pressure pain threshold at the trapezius and neck bilateral
Study: NCT03503656

Intervention type: DEVICE
Intervention: epidural catheter placement
Description: insertion of an epidural catheter using Compuflo System
Study: NCT03355222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of chicken eggs
Description: Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
Study: NCT02502851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting/Scoring Balloon
Description: Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
Study: NCT03899844

Intervention type: OTHER
Intervention: Blood collection, PiB PET/MRI, and cognitive testing
Description: Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
Study: NCT01456754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low feeding frequency (3x)
Description: 3 meals a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High feeding frequency (14x)
Description: 14 meals a day
Study: NCT02081027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02116933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Derived Stem Cells
Description: Adipose derived stem cells harvested from autologous lipoaspirate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Derived Stem Cells
Description: Adipose derived stem cells harvested from autologous lipoaspirate
Study: NCT01200394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Tablet, 20 mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, placebo once daily for 12 weeks
Study: NCT02784717

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Study: NCT03010202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Comparing the effect of Rituximab infusion With or without Dexamethasone
Study: NCT01220011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic laser surgery
Description: Fetoscopic laser surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetoscopic laser surgery
Description: Fetoscopic laser surgery